Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)

McGill University

$120,000.00

Repurposing fluoxetine as a novel therapeutic for spinocerebellar ataxia type 6

EF 2025-26

Résumé
Spinocerebellar ataxia type 6 (SCA6) is a rare, inherited neurodegenerative disease primarily affecting the cerebellum that leads to progressive problems with motor coordination and balance (ataxia) starting at midlife. This condition significantly impacts a person's quality of life, yet there are currently no available treatments to slow or stop this disease. Dysfunction in the expression and signaling of brain-derived neurotrophic factor (BDNF), a protein with important roles in neuronal survival and growth, and its receptor tropomyosin-related kinase B (TrkB) has been shown to contribute to SCA6. Interestingly, Prozac (fluoxetine), an FDA-approved antidepressant, has been shown to act on this pathway to enhance signalling and expression of BDNF and TrkB. In this study, we will investigate the efficacy of Prozac in alleviating ataxia in a mouse model of SCA6. We will also examine whether SCA6 patients who take antidepressants like Prozac experience a slower disease progression. Repurposing existing medications like Prozac could provide a safe, affordable, and quickly translatable treatment option for people living with SCA6 and other ataxias where BDNF and TrkB signaling is affected. Ultimately, this work aims to enhance the quality of life in patients with SCA6 and other ataxias.
Programme
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
560260
Name
Abdelhalim Rana
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
DT1 (Biomedical and/or Clinical Research) CGRS Doctoral
Projecttitle
Repurposing fluoxetine as a novel therapeutic for spinocerebellar ataxia type 6
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Anti-Depressant; Bdnf; Cerebellum; Fluoxetine; Motor Coordination; Phospho-Akt; Phospho-Erk; Purkinje Cells; Spinocerebellar Ataxia; Trkb
Abstract
Spinocerebellar ataxia type 6 (SCA6) is a rare, inherited neurodegenerative disease primarily affecting the cerebellum that leads to progressive problems with motor coordination and balance (ataxia) starting at midlife. This condition significantly impacts a person's quality of life, yet there are currently no available treatments to slow or stop this disease. Dysfunction in the expression and signaling of brain-derived neurotrophic factor (BDNF), a protein with important roles in neuronal survival and growth, and its receptor tropomyosin-related kinase B (TrkB) has been shown to contribute to SCA6. Interestingly, Prozac (fluoxetine), an FDA-approved antidepressant, has been shown to act on this pathway to enhance signalling and expression of BDNF and TrkB. In this study, we will investigate the efficacy of Prozac in alleviating ataxia in a mouse model of SCA6. We will also examine whether SCA6 patients who take antidepressants like Prozac experience a slower disease progression. Repurposing existing medications like Prozac could provide a safe, affordable, and quickly translatable treatment option for people living with SCA6 and other ataxias where BDNF and TrkB signaling is affected. Ultimately, this work aims to enhance the quality of life in patients with SCA6 and other ataxias.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Abdelhalim, Rana
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~